{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-137165","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.772847+00:00","generated_at":"2026-06-15T16:54:54.934507+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Reneo Pharmaceuticals prices public offering of 6.875M shares at $8.00, expects net proceeds ~$58.2M","bullets":["Public offering of 6.875M shares at $8.00/share; underwriters exercised overallotment for 1.031M additional shares in full.","Net proceeds expected approx. $58.2M after underwriting discounts and expenses.","Concurrent $5.0M private placement to Abingworth Bioventures at same $8.00/share, closing conditioned on public offering.","Offering expected to close May 8, 2023; shares sold under effective S-3 shelf registration.","Jefferies, BofA Securities, and Piper Sandler act as joint book-running managers."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-137165","json":"https://secwatch.observer/filing/0001193125-23-137165.json","markdown":"https://secwatch.observer/filing/0001193125-23-137165.md","text":"https://secwatch.observer/filing/0001193125-23-137165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523137165/0001193125-23-137165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523137165/d362041d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:54:54.934507+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"54ba442dff7c61a720784569cd7e570e25048a7d","claim":"OnKure Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters valued at 6,875,000 shares of common stock at $8.00 per share; additional 1,031,250 shares option exercised; n (effective 2023-05-03).","evidence_excerpt":"On May 3, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule A thereto (collectively, the “Underwriters”), relating to an offering (the “Public Offering”) of 6,875,000 shares (the “Shares”) of the Company’s common stock, $0.0001 par value per share (“Common Stock”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523137165/0001193125-23-137165-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Jefferies LLC, BofA Securities, Inc. and Piper Sandler & Co., as representatives of the several underwriters"},{"label":"Value","value":"6,875,000 shares of common stock at $8.00 per share; additional 1,031,250 shares option exercised; n"},{"label":"Effective","value":"2023-05-03"}],"fact_type":"material_agreement"},{"claim_id":"572b8a04b45449c24ead8a5d729ce1fb61d2bc9a","claim":"OnKure Therapeutics, Inc. entered into Securities Purchase Agreement with Abingworth Bioventures 8 LP valued at 625,000 shares of common stock at $8.00 per share; total purchase price approx. $5.0 million (effective 2023-05-02).","evidence_excerpt":"On May 2, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with Abingworth Bioventures 8 LP. (“Abingworth”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000119312523137165/0001193125-23-137165-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Abingworth Bioventures 8 LP"},{"label":"Value","value":"625,000 shares of common stock at $8.00 per share; total purchase price approx. $5.0 million"},{"label":"Effective","value":"2023-05-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}